Completed

Alternative Treatments for Premenstrual Dysphoric Disorder

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

LWT+AM BWL

+ EWT+PM BWL

Other
Who is being recruted

Behavior+8

+ Mental Disorders

+ Behavioral Symptoms

From 18 to 45 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: June 2013
See protocol details

Summary

Principal SponsorUniversity of California, San Diego
Last updated: February 4, 2022
Sourced from a government-validated database.Claim as a partner

Study start date: June 18, 2013

Actual date on which the first participant was enrolled.

The design is a randomized cross-over contrasting Late Wake Therapy plus morning bright light (LWT+Am BWL)vs. Early Wake Therapy plus evening bright light (EWT+PM BWL)administered in the luteal phase of two separate menstrual cycles, and preceded by 2 evaluation months. To lessen the patient's burden, the 1-night EWT or LWT and the following 7-day BWL interventions will be conducted at home, given at a fixed point in each menstrual cycle, from day 1 to 7 after the mid-cycle luteinizing hormone(LH) surge (ovulation). We anticipate that LWT+7 days of AM BWL (vs. EWT+PM BWL) will produce much greater mood benefits and larger physiological responses, than the one-time light pulses used in our earlier phase-shift studies.

Principal SponsorUniversity of California, San Diego
Last updated: February 4, 2022
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

43 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 45 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

BehaviorMental DisordersBehavioral SymptomsDepressive DisorderMenstruation DisturbancesPathologic ProcessesPremenstrual SyndromePathological Conditions, Signs and SymptomsMood DisordersDepressionPremenstrual Dysphoric Disorder

Criteria

Inclusion Criteria: Age: 18-45 years. Women with regular ovulatory menstrual cycles 26-32 days in length (for at least the previous six months). A history of a depressive (but not bipolar) mood disorder, but not an ongoing episode (symptom free for the last 12 months). Patients must meet DSM-IV criteria for Premenstrual Dysphoric Disorder (that includes irritability). Objective ratings: mean HRSD < 7 for follicular phase (day 5-10 of cycle after menses); mean HRSD > 14 for premenstrual (luteal) phase (6 days prior to onset of menses onward). Subjective ratings: mean Beck Depression Inventory < 5 follicular phase; > 10 premenstrual (luteal) phase, or Daily ratings: minimal symptoms (mean less than 50 on 100mm scale) follicular phase; at least a 30% increase in mean affective symptom ratings, premenstrual (luteal) phase. By clinical assessment and ratings, the patient has reported a history (for at least the last six months) of recurrent, moderate to severe premenstrual mood symptoms that impair some aspect of social or occupational functioning and that remit within a few days after the onset of menses. This pattern is prospectively documented with subjective and objective ratings over a 2-3 month interval. Patients must demonstrate a consistency of symptoms and a long enough duration of symptoms (7-10 days) to allow for study. Subjects willing to endure the rigors of a long-term (up to 6 months) research study. Exclusion Criteria: Subjects with significant medical illness including hepatic (abnormal liver function tests), neurological, renal, cardiac, pulmonary, hematologic, gastrointestinal, or metabolic disorders. Subjects who are lactating, are within 6 months postpartum, or have an irregular sleep- wake cycle, e.g., from having very young children in the home. Subjects who are using hormonal contraception (within six months prior to the study). Subjects using other medication within one month of initiating the study or anytime during the study. Subjects with significant psychiatric disorder (schizophrenia, bipolar disorder, anxiety disorders, eating disorders, personality disorders, sleep disorders). An ongoing major depressive episode within the last year is reason for exclusion, although a previous history of a depressive episode is not (using DSM-IV diagnostic criteria for a major depressive episode). Subjects with a recent history (within the past year) of drug or alcohol abuse. Subjects with clinically significant abnormal laboratory values. Subjects with irregular menstrual cycles (cycle lengths vary greater than 3 days). Subjects unlikely to cooperate with the requirements of the study. Subjects needing frequent or continuous use of any medication, including nicotine (> 5 cigarettes daily). Subjects whose prospective ratings do not show cyclic variation in association with the menstrual cycle (as per inclusion criteria). Subjects with an irregular sleep schedule, extreme chronotypes or a sleep-wake cycle that does not correspond to the environmental light-dark cycle (e.g., subjects within 2 weeks of transmeridian travel, night shift workers, or those with significant advanced or delayed sleep phase syndromes). To enhance precision of the timing of the light stimulus on circadian phase (temporal resolution), we will exclude women with habitual sleep onset times after midnight or wake times after 9 am.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator
Late-wake therapy in combination with morning bright white light

Group II

Placebo
Early-wake therapy in combination with evening bright white light

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

UCSD Medical Center, Hillcrest

San Diego, United StatesOpen UCSD Medical Center, Hillcrest in Google Maps
CompletedOne Study Center